An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Olson, Ashley D ^a   Meyer, Laurence ^b   Prins, Maria ^c   Thiebaut, Rodolphe ^b   Gurdasani, Deepti ^d,e   Guiguet, Marguerite ^b,f   Chaix, Marie Laure ^g   Amornkul, Pauli ^h   Babiker, Abdel ^a   Sandhu, Manjinder S ^d,e   Porter, Kholoud ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h International AIDS Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; SEROCONVERSION; COHORT ANALYSIS; COOPERATION; DEMOGRAPHY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; PROPORTIONAL HAZARDS MODEL; TIME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COOPERATIVE BEHAVIOR; DEMOGRAPHY; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; TIME FACTORS;

EID: 84900338995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086719     Document Type: Article

References (33)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954. (Pubitemid 27255797)
2. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, et al. (1996) Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 334: 426-431. (Pubitemid 26055842)
3. Thiebaut R, Matheron S, Taieb A, Brun-Vezinet F, Chene G, et al. (2011) Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS 25: 865-867.
4. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, et al. (1995) Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 332: 209-216.
5. Strathdee SA, Veugelers PJ, Page-Shafer KA, McNulty A, Moss AR, et al. (1996) Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 10: 959-965. (Pubitemid 26252625)
6. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, et al. (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200: 1714-1723.
7. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41: 1053-1056. (Pubitemid 41368233)
8. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416. (Pubitemid 47418678)
9. Chen H, Li C, Huang J, Cung T, Seiss K, et al. (2011) CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121: 1549-1560.
10. O'Connell KA, Bailey JR, Blankson JN (2009) Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30: 631-637.
11. Carrington M, O'Brien SJ (2003) The influence of HLA genotype on AIDS. Annu Rev Med 54: 535-551. (Pubitemid 37386411)
12. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, et al. (2010) Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 51: 233-238.
13. Baker BM, Block BL, Rothchild AC, Walker BD (2009) Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 9: 55-69.
14. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, et al. (2009) Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 83: 329-335.
15. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571. (Pubitemid 351321534)
16. Walker BD (2007) Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 15: 134-136.
17. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C (2011) Elite controllers as a model of functional cure. Curr Opin HIV AIDS 6: 181-187.
18. Okulicz JF (2012) Elite Controllers and Long-term Nonprogressors: Models for HIV Vaccine Development? J AIDS Clinic Res.
19. Eriksson EM, Milush JM, Ho EL, Batista MD, Holditch SJ, et al. (2012) Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood 119: 745-755.
20. Lopez M, Soriano V, Peris-Pertusa A, Rallon N, Restrepo C, et al. (2011) Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. AIDS Res Hum Retroviruses 27: 157-165.
21. Okulicz JF, Grandits GA, Weintrob AC, Landrum ML, Ganesan A, et al. (2010) CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 50: 1187-1191.
22. Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, et al. (2010) HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 24: 1095-1105.
23. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, et al. (2011) Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 118: 955-964.
24. de Wolf F, Sabin C, Kirk O, Thorne C, Chene G, et al. (2012) Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clinical Investigation 2: 255-264.
25. Gurdasani D, Iles L, Dillon D, Young E, Olson A, et al. (2013) A Systematic Review of Definitions of Extreme Phenotypes of HIV Control and Progression. AIDS In Press.
26. Thiebaut R, Jacqmin-Gadda H, Babiker A, Commenges D (2005) Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med 24: 65-82. (Pubitemid 40074065)
27. Madec Y, Boufassa F, Porter K, Meyer L (2005) Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19: 2001-2007. (Pubitemid 41669025)
28. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L (2005) Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 40: 1350-1354. (Pubitemid 40570247)
29. Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, et al. (2011) CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 6: e18726.
30. Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, et al. (2012) Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One 7: e29844.
31. Lefrere JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, et al. (1997) Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 90: 1133-1140. (Pubitemid 27314149)
32. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, et al. (2009) Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 200: 984-990.
33. Sajadi MM, Constantine NT, Mann DL, Charurat M, Dadzan E, et al. (2009) Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 50: 403-408.